EW financials
Edwards Lifesciences Corporation · end-of-day data as of Oct 16, 2026
Edwards Lifesciences Corporation
$86.60+4.8%
Buy · 30 analystsPT $99.77 +15.2%
EW reported revenue of $1.74B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 13.6% from a year earlier. It posted diluted EPS of $0.42, free cash flow of $585M and a net margin of 13.9%.
Valuation
- P/E49.8x
- P/E vs own+14.0%
- P/E vs sector+76.8%
- FCF yield+2.9%
- Market cap$49.9B
Quarterly results
Q2 FY2026: Revenue +13.6% year over year, free cash flow 33.6% of revenue, operating margin 29.8%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $1.74B | 0.42 | $585M | 77.6% | 29.8% | 13.9% |
| Q1 FY2026 | Mar 31, 2026 | $1.65B | 0.66 | -$21.1M | 78.2% | 31.2% | 23.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.57B | 0.16 | $354M | 78.3% | 23.6% | 5.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.55B | 0.50 | $516M | 77.9% | 27.4% | 18.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.53B | 0.56 | $241M | 77.6% | 28.1% | 21.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.41B | 0.61 | $224M | 78.7% | 27.9% | 25.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.39B | 0.65 | -$177M | 78.9% | 22.6% | 27.8% |
| Q3 FY2024 | Sep 30, 2024 | $1.35B | 5.13 | $320M | 80.6% | 25.9% | 226.7% |
| Q2 FY2024 | Jun 30, 2024 | $1.39B | 0.61 | $286M | 78.5% | 26.3% | 26.2% |
| Q1 FY2024 | Mar 31, 2024 | $1.33B | 0.58 | -$139M | 78.2% | 26.7% | 26.5% |
| Q4 FY2023 | Dec 31, 2023 | $1.27B | 0.61 | $35M | 80.2% | 28.2% | 29.2% |
| Q3 FY2023 | Sep 30, 2023 | $1.24B | 0.63 | $356M | 78.1% | 27.9% | 31.0% |